Vista Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis
VISTAPH
Pharmaceuticals
Screen Vista Pharmaceuticals share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price BSE
₹8.37
▼
-0.06 (-0.71%)
Market Cap
₹52.91 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
1.14
EPS (TTM)
₹-0.79
Dividend Yield
-
Debt to Equity
0.18
52W High
₹12.49
52W Low
₹7.65
Operating Margin
-99.00%
Profit Margin
-77.78%
Revenue (TTM)
₹9.00
EBITDA
₹-7.00
Net Income
₹-7.00
Total Assets
₹60.00
Total Equity
₹45.00
Vista Pharmaceuticals Share Price History - Stock Screener Chart
Screen VISTAPH historical share price movements with interactive charts. Analyze price trends and patterns.
Vista Pharmaceuticals Company Profile - Fundamental Screener
Screen Vista Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for VISTAPH shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE427C01021
Vista Pharmaceuticals Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen VISTAPH balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 60 | 58 | 56 | 56 | 51 | 51 | 53 | 53 | 42 | 26 |
| Current Assets | 25 | 23 | 24 | 24 | 15 | 21 | 23 | 28 | 26 | 16 |
| Fixed Assets | 19 | 19 | 20 | 19 | 20 | 21 | 21 | 18 | 14 | 10 |
| Liabilities | ||||||||||
| Total Liabilities | 60 | 58 | 56 | 56 | 51 | 51 | 53 | 53 | 42 | 26 |
| Current Liabilities | 3 | 3 | 5 | 8 | 9 | 6 | 6 | 6 | 6 | 8 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 45 | 41 | 37 | 36 | 33 | 30 | 36 | 32 | 17 | 11 |
| Share Capital | 12 | 9 | 8 | 7 | 7 | 6 | 6 | 6 | 5 | 5 |
| Reserves & Surplus | 33 | 26 | 23 | 28 | 26 | 24 | 30 | 26 | 11 | 6 |
Screen VISTAPH income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9 | 11 | 11 | 1 | 1 | 2 | 27 | 34 | 29 | 24 | 15 | 14 |
| Expenses | 16 | 14 | 14 | 5 | 2 | 3 | 28 | 30 | 24 | 21 | 13 | 11 |
| EBITDA | -7 | -4 | -3 | -4 | -1 | -2 | -1 | 4 | 6 | 3 | 3 | 3 |
| Operating Profit % | -99.00% | -40.00% | -32.00% | -443.00% | -321.00% | -137.00% | -21.00% | 4.00% | 18.00% | 13.00% | 17.00% | 20.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 0 |
| Profit Before Tax | -8 | -5 | -5 | -6 | -3 | -4 | -4 | 1 | 3 | 1 | 1 | 1 |
| Tax | 0 | -1 | -1 | 0 | -2 | -2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Net Profit | -7 | -5 | -5 | -6 | -1 | -2 | -4 | 1 | 2 | 1 | 1 | 1 |
| EPS | -1.50 | -0.79 | -1.03 | -1.54 | -0.24 | -0.54 | -1.22 | 0.31 | 0.76 | 0.46 | 0.31 | 0.54 |
Vista Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen VISTAPH cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -7 | -5 | -2 | -1 | -7 | 1 | 3 | -5 | 3 | -3 |
| Investing Activities | 0 | -1 | -1 | 0 | 0 | -2 | -6 | -11 | -4 | 0 |
| Financing Activities | 8 | 6 | 3 | 1 | 7 | 0 | 1 | 11 | 6 | 3 |
| Net Cash Flow | 1 | 0 | 0 | 0 | 0 | -1 | -1 | -4 | 5 | 0 |
Screen VISTAPH shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 27.81% | 27.81% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.03% | 0.03% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 33.64% | 33.62% | 33.62% | 34.00% | 33.86% | 33.44% | 35.43% | 35.43% |
| Other Holding | 45.16% | 45.17% | 45.17% | 44.79% | 44.93% | 45.36% | 36.74% | 36.74% |
| Shareholder Count | 14,012 | 14,061 | 14,158 | 14,086 | 13,913 | 13,882 | 14,015 | 13,908 |
Vista Pharmaceuticals Dividend Screener - Share Yield Analysis
Screen VISTAPH dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Vista Pharmaceuticals Index Membership - Market Screener Classification
Screen VISTAPH by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Vista Pharmaceuticals Market Events Screener - Corporate Actions
Screen VISTAPH market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 4.18% | ||
| Annual General Meeting | NA | -12.39% | ||
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | -0.83% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | 4.83% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -0.27% |
| 2025-03-20 | 2025-03-20 | Extraordinary General Meeting | NA | -0.65% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | 11.02% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | -1.49% |
| 2024-03-06 | 2024-03-06 | Extraordinary General Meeting | NA | -9.45% |
Vista Pharmaceuticals Competitors Screener - Peer Comparison
Screen VISTAPH competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 424,634 | 39.93 | 54,729 | 9.71% | 10,980 | 49.55 |
| Divis Laboratories | 172,860 | 69.20 | 9,712 | 18.67% | 2,191 | 56.33 |
| Torrent Pharmaceuticals | 129,151 | 60.10 | 11,539 | 6.99% | 1,911 | 61.47 |
| Cipla | 122,205 | 22.55 | 28,410 | 7.12% | 5,291 | 49.47 |
| Dr Reddys Laboratories | 107,114 | 18.60 | 33,741 | 16.73% | 5,725 | 60.05 |
| Lupin | 97,120 | 22.34 | 22,910 | 13.74% | 3,306 | 65.28 |
| Zydus Life Science | 92,392 | 18.40 | 23,511 | 18.55% | 4,615 | 40.07 |
| Mankind Pharma | 90,241 | 50.59 | 12,744 | 20.90% | 2,007 | 45.53 |
| Aurobindo Pharma | 71,119 | 20.79 | 32,346 | 9.43% | 3,484 | 59.88 |
| Alkem Laboratories | 67,243 | 27.59 | 13,458 | 3.70% | 2,216 | 49.80 |
Vista Pharmaceuticals Company Announcements - News Screener
Screen VISTAPH latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-11-13 | Board Meeting Outcome for Un Audited Financial Results For The Quarter And Half Year Ended 30.09.2025 | View |
| 2025-11-13 | Un Audited Financials Results For The Quarter And Half Year Ended 30.09.2025 | View |
| 2025-11-04 | Board Meeting Intimation for 1. Unaudited Financial Results For The Quarter Ended 30.09.2025. 2. Limited Review Report For Quarter Ended 30.09.2025. 3. Any Other Business With The Permission Of The Chair. | View |
| 2025-10-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-30 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-09-30 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-09-25 | Closure of Trading Window | View |
| 2025-09-09 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-09-08 | Intimation Of Book Closure Regarding 34" Annual General Meeting | View |
| 2025-09-08 | Reg. 34 (1) Annual Report. | View |
| 2025-09-08 | 34Th Annual General Meeting Of Vista Pharmaceuticals Limited On Tuesday 30Th September 2025 | View |
| 2025-08-13 | Re-Appointment Of Mr. Murali Meraga (DIN: 02537507) As An Managing Director Of The Company | View |
| 2025-08-13 | Re-Appointment Of Mr. Pavan Sathvik Gilaka (DIN: 09733182) As An Whole Time Director Of The Company | View |
| 2025-08-13 | Re-Appointment Of Mr. Dhananjaya Alli (DIN: 00610909) As An Whole Time Director Of The Company | View |
| 2025-08-13 | Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter Ended 30.06.2025 | View |
| 2025-08-13 | Results - Unaudited Financial Results For The Quarter Ended 30.06.2025 | View |
| 2025-08-06 | Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended 30.06.2025 | View |
| 2025-07-16 | Outcome Of Circular Resolution Passed By Board Of Directors Of The Company By Circulation On July 16 2025 Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | View |
| 2025-07-15 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-06-27 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements Requirements) Regulations 2015. | View |